Refine by
Novel Bispecific Fusion Protein Equipment & Supplies
5 equipment items found
by:GI Innovation based inSeoul, SOUTH KOREA
Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the immuno-suppressive function of regulatory T cells (Tregs) in tumor microenvironment (TME). Restores T cell function and anti-cancer immune responses in TME. Secures its safety in GLP toxicity ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: CAR iNK cells + novel receptor fusion proteins. ...
by:Horizon Therapeutics plc based inSaint Kevin`s, IRELAND
Exclusive collaboration to develop novel, multi-specific fusion protein based therapies for autoimmune and inflammatory ...
Manufactured by:Ocugen, Inc. based inMalvern, PENNSYLVANIA (USA)
OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age-Related Macular Degeneration (Wet-AMD). Patients affected by these diseases share common symptoms, such as blurriness in vision and progressive vision loss as the disease progresses. The formation of fragile ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune ...